FDA Approves Generic Lanreotide, Challenging Somatuline Depot Market
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
The U.S. Food and Drug Administration approved a generic lanreotide injection for immediate launch, referencing Somatuline Depot. This generic was designated as a Competitive Generic Therapy and is used to treat acromegaly, advanced gastro-enteropancreatic neuroendocrine tumors, and carcinoid syndrome. The reference drug, Somatuline Depot, generated $983 million in annual U.S. sales for the year ended July 2026.
Why it matters
The approval introduces a new competitor to a specialty injectable market that previously generated nearly a billion dollars in U.S. brand sales. This increased generic competition could pressure domestic pricing and market share in regions like India.
From medicaldaily.com
Who's involved
- FDARegulatory agency that approved the generic lanreotide injection.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- IndiaSpeculative
Might face pressure on domestic pricing and market share due to increased generic competition in the specialty injectable market.
Keep exploring
The entities involved
Related events
- Inventiva seeks FDA approval for lanifibranor in the U.S. market.
- The FDA is currently reviewing new drug applications for market entry.
- FDA and Pfizer are seeking regulatory approval for their products.
- Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.